(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -6.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Arrowhead Pharmaceuticals's revenue in 2026 is $622,009,000.On average, 16 Wall Street analysts forecast ARWR's revenue for 2026 to be $64,740,703,992, with the lowest ARWR revenue forecast at $43,206,482,622, and the highest ARWR revenue forecast at $94,655,918,112. On average, 15 Wall Street analysts forecast ARWR's revenue for 2027 to be $45,208,060,890, with the lowest ARWR revenue forecast at $15,764,717,790, and the highest ARWR revenue forecast at $74,719,015,360.
In 2028, ARWR is forecast to generate $82,335,154,485 in revenue, with the lowest revenue forecast at $44,172,761,786 and the highest revenue forecast at $150,294,441,407.